World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
73958
World Ranking
8720
National Ranking
4495

Joseph P. Costantino publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Joseph P. Costantino sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 305 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Joseph P. Costantino D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph P. Costantino sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Joseph P. Costantino is affiliated with the University of Pittsburgh in the United States. Their research covers multiple fields within medicine, particularly focusing on oncology, molecular biology, and genetics, alongside contributions to nephrology and cardiology and cardiovascular medicine.

Their work predominantly addresses topics such as amyloidosis diagnosis and treatment, parathyroid disorders, breast cancer treatment studies, cancer treatment and pharmacology, prostate cancer research, neuroendocrine tumor advances, and cardiomyopathy and myosin studies.

Costantino has published in a variety of venues, with frequent contributions to the following journals:

  • European Heart Journal Supplements
  • Cancer Research
  • EP Europace
  • New England Journal of Medicine
  • Journal of Clinical Oncology

Notable papers include:

  • "Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer," 2021, New England Journal of Medicine
  • "Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer," 2023, Journal of Clinical Oncology
  • "Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)," 2020, Cancer Research
  • "Landmark Proportional Subdistribution Hazards Models for Dynamic Prediction of Cumulative Incidence Functions," 2020, Journal of the Royal Statistical Society Series C (Applied Statistics)
  • "Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze," 2020, Cancer Research

The scientist frequently collaborates with several researchers, including:

  • F Ballatore
  • Carmine Dario Vizza
  • Cristina Chimenti
  • Giulia Manguso
  • Maria Alfarano

Joseph P. Costantino's diverse scholarship reflects a multidisciplinary approach, combining clinical oncology research and molecular biology with statistical models and cardiovascular medicine. Their contributions span both clinical trial results and methodological advancements in prediction modeling.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

    Victor G. Vogel;Joseph P. Costantino;D. Lawrence Wickerham;Walter M. Cronin

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

    Soonmyung Paik;Gong Tang;Steven Shak;Chungyeul Kim

  • Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

    David N. Krag;Stewart J. Anderson;Thomas B. Julian;Ann M. Brown

  • Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

    Victor G. Vogel;Joseph P. Costantino;D. Lawrence Wickerham;D. Lawrence Wickerham;Walter M. Cronin

  • A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors

    Fisher B;Costantino J;Redmond C;Poisson R

  • Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14

    Fisher B;Costantino Jp;Redmond Ck;Fisher Er

  • Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

    Bernard Fisher;Joseph P. Costantino;D. Lawrence Wickerham;Reena S. Cecchini

  • Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial

    David N Krag;Stewart J Anderson;Thomas B Julian;Ann M Brown

  • Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer

    B Fisher;J Costantino;C Redmond;E Fisher

  • Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17

    B. Fisher;J. Dignam;N. Wolmark;E. Mamounas

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

    Bernard Fisher;James Dignam;John Bryant;Arthur DeCillis

  • Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence

    J P Costantino;M H Gail;D Pee;S Anderson

  • Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer

    Mitchell H. Gail;Joseph P. Costantino;John Bryant;Robert Croyle

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

    Irene L. Wapnir;James J. Dignam;Bernard Fisher;Eleftherios P. Mamounas

  • Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

    Clifford A. Hudis;William E. Barlow;Joseph P. Costantino;Robert J. Gray

  • Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

    Mary Claire King;Sam Wieand;Kathryn Hale;Ming Lee

Frequent Co-Authors

Norman Wolmark
Norman Wolmark University of Pittsburgh
Eleftherios P. Mamounas
Eleftherios P. Mamounas University of Florida Health
Soonmyung Paik
Soonmyung Paik Yonsei University
Sandra M. Swain
Sandra M. Swain Georgetown University Medical Center
Patricia A. Ganz
Patricia A. Ganz University of California, Los Angeles
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Bernard Fisher
Bernard Fisher University of Pittsburgh
Charles E. Geyer
Charles E. Geyer University of Pittsburgh
Edwin R. Fisher
Edwin R. Fisher University of Pittsburgh
Adam Brufsky
Adam Brufsky University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring diverse online degrees can open doors to various career paths in the healthcare sector. For those looking to advance quickly, easy dnp programs offer a flexible path to a Doctor of Nursing Practice, designed for working professionals seeking leadership roles.

If you're interested in entering the workforce sooner, consider a fast lpn program, which provides accelerated training for licensed practical nurses. This is ideal for individuals looking for a fast entry into patient care positions without a lengthy degree commitment.

Specializing in mental health is another in-demand area. The shortest post master's pmhnp online programs enable current nurses to efficiently move into psychiatric-mental health nurse practitioner roles.

For those interested in the business side of medicine, an online health care administration degree online prepares students for leadership opportunities in hospital and clinic management, with several affordable options available.

Best Scientists Citing Joseph P. Costantino

Trending Scientists

Recently Published Articles